Brief: Fulcrum Therapeutics - As Of September 30, 2023, Cash, Cash Equivalents, And Marketable Securities Were $257.1 Million

Fulcrum Therapeutics

07/11/2023 12:10

Nov 7 (Reuters) - Fulcrum Therapeutics Inc  FULC.O :
    * AS OF SEPTEMBER 30, 2023, CASH, CASH EQUIVALENTS, AND
MARKETABLE
SECURITIES WERE $257.1 MILLION
    * COLLABORATION REVENUE WAS $0.8 MILLION FOR Q3 OF 2023
    * FULCRUM THERAPEUTICS - EXPECTS EXISTING CASH, CASH
EQUIVALENTS,
& MARKETABLE SECURITIES TO BE SUFFICIENT TO FUND ITS OPERATING
REQUIREMENTS INTO 2026
    * QTRLY LOSS PER SHARE $0.39
    * Q3 EARNINGS PER SHARE VIEW $-0.44, REVENUE VIEW $1.1
MILLION --
LSEG IBES DATA

Source text for Eikon:  ID:nGNX86Rfx2 
Further company coverage:  FULC.O 

 ((Reuters.Briefs@thomsonreuters.com;))